Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

ONDANSETRON  IMPURITY D CRS (15 MG)

ONDANSETRON IMPURITY D CRS (15 MG)

99614-64-9

DISCOVER
ONDANSETRON  FOR TLC SYSTEM SUITABILITY CRS (20 MG)

ONDANSETRON FOR TLC SYSTEM SUITABILITY CRS (20 MG)

103639-04-9

DISCOVER
ONDANSETRON  FOR LC SYSTEM SUITABILITY CRS (10 MG)

ONDANSETRON FOR LC SYSTEM SUITABILITY CRS (10 MG)

103639-04-9

DISCOVER
CIPROFLOXACIN CRS (20 MG)

CIPROFLOXACIN CRS (20 MG)

85721-33-1

DISCOVER
CIPROFLOXACIN HYDROCHLORIDE FOR PEAK IDENTIFICATION CRS (10

CIPROFLOXACIN HYDROCHLORIDE FOR PEAK IDENTIFICATION CRS (10

86393-32-0

DISCOVER
MEXILETINE IMPURITY C CRS (10MG)

MEXILETINE IMPURITY C CRS (10MG)

NA

DISCOVER
MEXILETINE IMPURITY D CRS (15MG)

MEXILETINE IMPURITY D CRS (15MG)

NA

DISCOVER
Pravastatin 1,1,3,3-tetramethylbutylamine CRS, 30mg

Pravastatin 1,1,3,3-tetramethylbutylamine CRS, 30mg

NA

DISCOVER
CLOBAZAM - REFERENCE SPECTRUM(N/A)

CLOBAZAM - REFERENCE SPECTRUM(N/A)

NA

DISCOVER
PERINDOPRIL FOR STEREOCHEMICAL PURITY CRS (40 MG)

PERINDOPRIL FOR STEREOCHEMICAL PURITY CRS (40 MG)

107133-36-8

DISCOVER
DOXAPRAM IMPURITY B CRS (10 MG)

DOXAPRAM IMPURITY B CRS (10 MG)

NA

DISCOVER
Colchicine for system suitability 10 mg

Colchicine for system suitability 10 mg

64-86-8

DISCOVER